KR102750984B1 - A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof - Google Patents
A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof Download PDFInfo
- Publication number
- KR102750984B1 KR102750984B1 KR1020210149719A KR20210149719A KR102750984B1 KR 102750984 B1 KR102750984 B1 KR 102750984B1 KR 1020210149719 A KR1020210149719 A KR 1020210149719A KR 20210149719 A KR20210149719 A KR 20210149719A KR 102750984 B1 KR102750984 B1 KR 102750984B1
- Authority
- KR
- South Korea
- Prior art keywords
- protopanaxadiol
- protopanaxatriol
- wild ginseng
- fermented composition
- ginsenosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 84
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 81
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 title claims abstract description 40
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 title claims abstract description 40
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 title claims abstract description 37
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 title claims abstract description 35
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 title claims abstract description 32
- 241000208340 Araliaceae Species 0.000 title claims abstract description 12
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 title claims abstract 6
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 title claims abstract 6
- 241000228347 Monascus <ascomycete fungus> Species 0.000 title description 22
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 title description 4
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 title description 4
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 title description 4
- 238000002360 preparation method Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 6
- 235000020824 obesity Nutrition 0.000 claims abstract description 6
- 238000000855 fermentation Methods 0.000 claims description 32
- 230000004151 fermentation Effects 0.000 claims description 32
- 244000068988 Glycine max Species 0.000 claims description 19
- 235000010469 Glycine max Nutrition 0.000 claims description 19
- 229940057059 monascus purpureus Drugs 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 244000113306 Monascus purpureus Species 0.000 claims description 7
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 241000030999 Monascus pilosus Species 0.000 claims description 4
- 238000010025 steaming Methods 0.000 claims description 4
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 9
- 102000019280 Pancreatic lipases Human genes 0.000 abstract description 9
- 108050006759 Pancreatic lipases Proteins 0.000 abstract description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 9
- 229940116369 pancreatic lipase Drugs 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 7
- 235000002789 Panax ginseng Nutrition 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 description 73
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 30
- SHCBCKBYTHZQGZ-PHFGEWBZSA-N (3s,5r,6s,8r,9r,10r,12r,13r,14s,17s)-17-[(2s)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,6,12-triol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-PHFGEWBZSA-N 0.000 description 27
- 229930182494 ginsenoside Natural products 0.000 description 27
- 239000000523 sample Substances 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 16
- 238000002835 absorbance Methods 0.000 description 14
- 240000006439 Aspergillus oryzae Species 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 11
- 230000002292 Radical scavenging effect Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 229930003935 flavonoid Natural products 0.000 description 8
- 150000002215 flavonoids Chemical class 0.000 description 8
- 235000017173 flavonoids Nutrition 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 6
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 235000002791 Panax Nutrition 0.000 description 3
- 241000208343 Panax Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZTQSADJAYQOCDD-FDDSVCGKSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[[(3s,5r,8r,9r,10r,12r,13r,14r,17s)-12-hydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O ZTQSADJAYQOCDD-FDDSVCGKSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- BGHNZAWRRWLKPO-UHFFFAOYSA-N Ginsenoside F1 Natural products CC(=C)CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C BGHNZAWRRWLKPO-UHFFFAOYSA-N 0.000 description 1
- SWIROVJVGRGSPO-UHFFFAOYSA-N Ginsenoside F2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O SWIROVJVGRGSPO-UHFFFAOYSA-N 0.000 description 1
- AVTXSAWPGCSYFO-UHFFFAOYSA-N Ginsenoside Ia Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O AVTXSAWPGCSYFO-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001052469 Monascus kaoliang Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical class C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 238000004186 food analysis Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- XNGXWSFSJIQMNC-FIYORUNESA-N ginsenoside F1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@H](O)[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XNGXWSFSJIQMNC-FIYORUNESA-N 0.000 description 1
- SWIROVJVGRGSPO-JBVRGBGGSA-N ginsenoside F2 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SWIROVJVGRGSPO-JBVRGBGGSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/10—General methods of cooking foods, e.g. by roasting or frying
- A23L5/13—General methods of cooking foods, e.g. by roasting or frying using water or steam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명에서는 산양삼새싹을 홍국균으로 발효하여 제조한 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올과 항산화 활성, 알파-글루코시다아제 저해활성 및 췌장-리파아제 저해활성이 현저히 증진된 발효조성물 및 그 제조방법이 개시된다.
본 발명에 따른 산양삼새싹 홍국균 발효조성물은 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올이 고함량으로 함유되고, 항산화 활성, 당뇨 및 비만 개선 효과가 우수하여 기능성식품 및 화장품의 소재로 사용될 수 있다.The present invention discloses a fermented composition containing ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol, which are produced by fermenting wild ginseng sprouts with red ginseng fungus, and having significantly enhanced antioxidant activity, alpha-glucosidase inhibitory activity, and pancreatic lipase inhibitory activity, and a method for producing the same.
The fermented composition of wild ginseng sprouts and Honggukgyun according to the present invention contains a high content of ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol, and has excellent antioxidant activity and diabetes and obesity improvement effects, so that it can be used as a material for functional foods and cosmetics.
Description
본 발명은 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹 홍국균 발효조성물 및 그 제조방법에 관한 것으로, 더 상세하게는 산양삼새싹을 홍국균으로 발효하여 제조한 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올과 항산화 활성, 알파-글루코시다아제 저해활성, 및 췌장-리파아제 저해활성이 현저히 증진된 발효조성물 및 그 제조방법에 관한 것이다.The present invention relates to a fermented composition of wild ginseng sprouts and Hong Aspergillus oryzae, which is enhanced in ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, and a method for producing the same. More specifically, the present invention relates to a fermented composition prepared by fermenting wild ginseng sprouts with Hong Aspergillus oryzae, which is enhanced in ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, and which has significantly enhanced antioxidant activity, alpha-glucosidase inhibitory activity, and pancreatic lipase inhibitory activity, and a method for producing the same.
삼(Ginseng)은 재배환경에 따른 인위적인 성장과 자연적인 성장의 차이와 형태학적 차이 등에 따라 인삼(人蔘), 산삼(山蔘), 또는 산양삼(山羊蔘)으로 구분한다. 특히 산양삼은 오가피과에 속하며 다년생 초목인 인삼(Panax ginseng)이 산간의 삼림하의 야생상태에서 자연적으로 성장한 산삼의 씨앗이나 유삼을 인위적으로 산에서 재배한 것을 말하며 이들을 산양삼이라 한다. 인삼의 경우에는 대부분 노두(머리 부분)가 3-7개 정도이나 산양삼은 연령에 따라 그 이상인 것이 많으며 인삼의 뿌리는 굵고 짧으나 산양삼은 길고 가늘다. 산양삼(山養蔘)이란 「산지관리법」 제2조 1호의 산지에서 재배하고 「임업 및 산촌 진흥촉진에 관한 법률」 제18조의 4에 따른 품질검사에 합격한 오갈피나무과(科) 인삼속(人蔘屬) 식물을 말한다. 산양삼은 고려인삼(高麗人蔘)의 인삼종으로 Panax ginseng C.A. Mey.라는 학명으로 불리며, 속명인 'Panax'는 만병통치약을 뜻한다. Ginseng is classified as ginseng, mountain ginseng, or sheep ginseng depending on the differences in artificial and natural growth depending on the cultivation environment, as well as morphological differences. In particular, sheep ginseng belongs to the Araliaceae family and refers to the seeds or young ginseng of ginseng ( Panax ginseng ), a perennial herb, that have grown naturally in the wild under mountain forests, and these are called sheep ginseng. In the case of ginseng, most have 3-7 heads, but sheep ginseng often has more depending on age. In addition, the roots of ginseng are thick and short, but sheep ginseng is long and thin. Cultivated ginseng refers to a plant of the genus Panax in the family Acanthopanax that is cultivated in a mountain area as defined in Article 2, Paragraph 1 of the Mountain Area Management Act and that has passed the quality inspection as defined in Article 18, Section 4 of the Forestry and Mountain Village Development Promotion Act. Cultivated ginseng is a species of ginseng of the Korean ginseng family and is called Panax ginseng CA Mey. Its scientific name is Panax, and its common name, Panax, means a cure-all.
진세노사이드는 트리터펜노이드(triterpenoid)의 담마란네(dammarane)계의 인삼 속의 식물에만 존재하는 특유 사포닌이다. 기본 골격의 탄소 3, 6, 및 20번의 위치에 글루코스, 자일로스 및 람노스 등의 당을 결하는 형태의 구조를 가지며 이들은 프로토파낙사디올(protopanaxadiol), 프로토파낙사트리올(protopanaxatriol), 올래놀익산(oleanolic acid), 및 옥틸롤(octillol) 계열로 나눠지며, 약성이 매우 온화하고 과량투여에 의한 독성이 없으며 용혈작용이 거의 없는 것으로 알려졌다. 프로토파낙사디올 계열은 진세노사이드 Rb1, Rb2, Rb3, Rc, Rd, 및 Rg1 등이 있으며, 프로토파낙사트리올 계열은 진세노사이드 Re, Rf, Rg1, 및 Rg2 등이 있다. 이러한 진세노사이드들은 여러 효능들이 알려져 있다. 대표적으로 항암, 항당뇨작용 및 면역기능 조절작용 등에 효능이 있다고 보고되었다. 보통 인삼은 뿌리만 식용으로 사용되고 있으며 이는 재배 년 수가 지날수록 잎의 경질화 등에 의해 식용이 어렵기 때문이다. 하지만 광합성과 관련이 있는 인삼의 잎에도 적지 않은 진세노사이드가 함유되어 있다고 보고되었다. Ginsenosides are unique saponins that exist only in plants of the ginseng genus in the dammarane series of triterpenoids. They have a structure in which sugars such as glucose, xylose, and rhamnose are bonded to carbon positions 3, 6, and 20 of the basic skeleton, and they are divided into protopanaxadiol, protopanaxatriol, oleanolic acid, and octillol series, and are known to have very mild pharmacological properties, no toxicity due to overdose, and almost no hemolytic effect. The protopanaxadiol series includes ginsenosides Rb1, Rb2, Rb3, Rc, Rd, and Rg1, and the protopanaxatriol series includes ginsenosides Re, Rf, Rg1, and Rg2. These ginsenosides are known to have various efficacies. It has been reported to have anticancer, antidiabetic, and immune function regulating effects. Usually, only the root of ginseng is used for food, and this is because it becomes difficult to eat due to hardening of the leaves as the number of years of cultivation passes. However, it has been reported that ginseng leaves, which are related to photosynthesis, also contain a considerable amount of ginsenoside.
산양삼새싹(mountain-cultivated ginseng sprout)은 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월에서 6월 사이 잎과 줄기 자란 것이나 혹은 산양삼 3년근 이상을 일정한 환경이 제어되는 시설(스마트팜 혹은 식물공장)에서 20일~120일 동안 잎과 줄기 자란 것을 칭한다. 산양삼새싹은 재배동안에는 환경이 제어되는 시설에서는 연중생산 가능하고 재배 기간의 짧아서 산업적 이용면에서 장점이 있어, 이의 가공품의 개발이 요구되고 있다.Mountain-cultivated ginseng sprouts refer to mountain-cultivated ginseng that is at least 3 years old and has leaves and stems grown in a forest at least 500 m above sea level between May and June, or mountain-cultivated ginseng that is at least 3 years old and has leaves and stems grown for 20 to 120 days in a facility with a controlled environment (smart farm or plant factory). Mountain-cultivated ginseng sprouts can be produced year-round in a facility with a controlled environment during cultivation, and because their short cultivation period has advantages in terms of industrial use, the development of processed products from them is demanded.
홍국균은 반자낭균과(Hemiascomycetaceae) 홍국균속(Monascaceae)에 속하며 현재 약 70종류가 분리되어 동정되어 있다. 증백미에 Monascus속 곰팡이를 배양하여 적색 색소를 내는 것이 특징으로 약 600년 전부터 동아시아권 국가에서 보존제, 수산 연제품, 축산가공품 등에 착색제, 소화 촉진제 등의 목적으로 사용되어왔다. 홍국균을 이용하여 발효시킨 커피 생두 발효물을 포함하는 항염증 및 면역증진용 조성물(한국특허등록: 제10-1492174)이 개시되어 있다.Monascus belongs to the genus Monascus in the family Hemiascomycetaceae, and about 70 species have been isolated and identified at present. It is characterized by producing a red pigment by culturing Monascus fungi in steamed rice, and has been used for the purpose of preservatives, coloring in marine products, and processed livestock products, and as a digestive aid in East Asian countries since about 600 years ago. An anti-inflammatory and immune-enhancing composition containing a fermented coffee bean product fermented using Monascus is disclosed (Korean Patent Registration No. 10-1492174).
그러나 산양삼새싹은 홍국균에 의한 성공적인 발효의 전례가 없을 뿐만 아니라, 특히 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진된 산양삼새싹 홍국균 발효조성물은 개발된 바 없다.However, not only is there no precedent for successful fermentation of wild ginseng sprouts using Hong Aspergillus oryzae, but in particular, a wild ginseng sprout fermentation composition with significantly increased ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol has not been developed.
이에 본 발명자들은 종래 기술의 요구에 부응하기 위한 연구를 지속한 결과, 산양삼새싹을 홍국균으로 발효한 경우, 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진됨을 확인하고 본 발명을 완성하게 되었다.Accordingly, the inventors of the present invention continued their research to meet the needs of the prior art, and as a result, they confirmed that when wild ginseng sprouts are fermented with Hongguk fungus, ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol are significantly increased, and thus completed the present invention.
따라서 본 발명의 목적은 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹의 홍국균 발효조성물을 제공하는 것이다.Therefore, the purpose of the present invention is to provide a fermented composition of wild ginseng sprouts with Hongsugung fungus, which is enriched with ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명의 또 다른 목적은 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 강화된 산양삼새싹의 홍국균 발효조성물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing a fermented composition of wild ginseng sprouts containing ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명의 또 다른 목적은 상기 산양삼새싹의 홍국균 발효조성물을 포함하는 기능성식품을 제공하는 것이다.Another object of the present invention is to provide a functional food containing a fermented composition of the above-mentioned wild ginseng sprouts and Hongguk fungus.
본 발명의 또 다른 목적은 본 발명의 산양삼새싹의 홍국균 발효조성물을 포함하는 화장품을 제공하는 것이다.Another object of the present invention is to provide a cosmetic comprising a fermented composition of the wild ginseng sprouts of the present invention.
상기 목적을 달성하기 위하여, 본 발명은 산양삼새싹과 콩의 혼합물을 홍국균으로 발효하여 제조된 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올이 강화된 산양삼새싹의 홍국균 발효조성물을 제공한다.To achieve the above object, the present invention provides a fermented composition of wild ginseng sprouts with Hong Aspergillus oryzae, which is produced by fermenting a mixture of wild ginseng sprouts and soybeans with Hong Aspergillus oryzae, and is enriched with ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol.
본 발명에서 산양삼새싹은 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월에서 6월 사이 잎과 줄기 자란 것이나 혹은 산양삼 3년근 이상을 일정한 환경이 제어되는 시설(스마트팜 혹은 식물공장)에서 20~120일 동안 잎과 줄기 자란 것을 칭하는 것으로, 바람직하게는 산양삼 3년근 이상을 해발 500m 이상 숲에서 5월 및 일정한 환경이 제어되는 시설에서 25~45일 동안 생육시켜 잎과 줄기가 자란 것을 사용하는 것이 바람직하다. In the present invention, wild ginseng sprouts refer to wild ginseng that is at least 3 years old and has leaves and stems grown in a forest at least 500 m above sea level between May and June, or wild ginseng that is at least 3 years old and has leaves and stems grown for 20 to 120 days in a facility (smart farm or plant factory) with a controlled environment. It is preferable to use wild ginseng that is at least 3 years old and has leaves and stems grown for 25 to 45 days in a forest at least 500 m above sea level in a facility with a controlled environment in May.
본 발명의 혼합물에서 산양삼새싹은 90~94 중량%, 콩은 6~10 중량%로 포함되는 것이 바람직하고, 가장 바람직하게는 산양삼새싹 90 중량% 및 콩 10 중량%가 포함된다. In the mixture of the present invention, it is preferable that the mountain ginseng sprouts are included in an amount of 90 to 94 wt% and the soybeans are included in an amount of 6 to 10 wt%, and most preferably, the mountain ginseng sprouts are included in an amount of 90 wt% and the soybeans are included in an amount of 10 wt%.
본 발명에서 콩은 주로 홍국균이 생육에 필요한 질소원의 역할을 하면서도 홍국균의 발효(물질전환작용)를 증진시키는 기능도 한다. In the present invention, soybeans mainly serve as a nitrogen source necessary for the growth of red yeast, while also having the function of promoting the fermentation (substance conversion) of red yeast.
산양삼새싹의 함량이 상기 범위를 벗어나면, 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올, 및 프로토파낙사디올의 함량이 떨어지며, 콩의 함량이 상기 범위를 벗어나면 홍국균의 균사 성장이 충분하지 않을 수 있다. 홍국균의 성장 정도와 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올의 함량을 모두 고려할 때 산양삼새싹 : 콩의 중량비는 9 : 1인 것이 가장 바람직하다. If the content of mountain ginseng sprouts is out of the above range, the contents of ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol decrease, and if the content of soybeans is out of the above range, the mycelial growth of Hong Aspergillus oryzae may not be sufficient. Considering both the growth degree of Hong Aspergillus oryzae and the contents of ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol, the weight ratio of mountain ginseng sprouts: soybeans is most preferably 9:1.
본 발명에서 산양삼새싹은 세척한 후 건조하고 세절하여 50~55℃에서 2~3일간 건조하여 사용하는 것이 바람직하며, 콩은 세척하고 물기를 제거한 것을 사용한다. In the present invention, it is preferable to use the wild ginseng sprouts after washing, drying, cutting, and drying them at 50-55℃ for 2-3 days, and the soybeans are used after washing and removing moisture.
본 발명에서 ‘홍국균’은 모나스쿠스(Monascus) 속의 진균을 의미한다. In the present invention, ‘Honggukgyun’ refers to a fungus of the genus Monascus .
본 발명에서 산양삼새싹 기질과 혼합 배양되는 홍국균은 모나스커스(Monascus) 속에 속하고 2차 대사산물로 모나콜린 K를 생성할 수 있는 균이라면 그 종류가 제한되지 않는다. 예를 들어, 본 발명에서 사용될 수 있는 홍국균은 모나스커스 필로서스(Monascus pilosus), 모나스커스 러버(Monascus ruber), 모나스커스 퍼프레우스(Monascus purpureus), 모나스커스 카올리앙(Monascus kaoliang), 모나스커스 바리케리(Monascus barykery), 모나스커스 안카(Monascus anka) 등이 있고, 모나콜린 K의 높은 생산성 및 시트리닌(citrinin)의 낮은 생산성을 고려할 때 모나스커스 필로서스(Monascus pilosus) 및/또는 모나스커스 퍼프레우스(Monascus purpureus)이 선택되는 것이 바람직하다. In the present invention, the red aspergillus oryzae fungus that is mixed-cultured with the wild ginseng sprout substrate is not limited in type as long as it belongs to the genus Monascus and can produce monacolin K as a secondary metabolite. For example, the red aspergillus oryzae fungus that can be used in the present invention include Monascus pilosus , Monascus ruber , Monascus purpureus, Monascus kaoliang, Monascus barykery , Monascus anka , etc., and considering the high productivity of monacolin K and the low productivity of citrinin, it is preferable to select Monascus pilosus and/or Monascus purpureus .
본 발명에서 '발효'는 홍국균을 종균으로 사용하여 발효하는 것을 의미한다. 산양삼새싹 및 콩의 혼합물을 홍국균으로 발효시, 놀랍게도 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 현저히 증진되었다 (표 1, 표 2).In the present invention, 'fermentation' means fermentation using Hong Aspergillus oryzae as a starter. When a mixture of wild ginseng sprouts and soybeans was fermented with Hong Aspergillus oryzae, surprisingly, ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol, and protopanaxadiol were significantly increased (Table 1, Table 2).
본 발명에서 홍국균은 산양삼새싹 및 콩의 혼합물에 3~10%(v/w) 농도로 접종하여 20~30℃에서 8~12일간 발효시키는 것으로 수행될 수 있다. 가장 바람직하게는 10일간 발효한다. In the present invention, the fermentation can be carried out by inoculating Honggukgyun in a mixture of wild ginseng sprouts and soybeans at a concentration of 3 to 10% (v/w) and fermenting at 20 to 30°C for 8 to 12 days. Most preferably, the fermentation is carried out for 10 days.
홍국균 접종량이 3%(v/w) 미만일 경우에는 발효 속도가 지연될 수 있고 10%(v/w) 초과시에는 균사체 증식 속도가 빨라 전환율이 낮을 수 있으며, 발효 온도가 20℃ 미만일 경우 발효기간이 길어져 잡균의 오염을 초래하고 30℃를 초과할 경우에는 균사체의의 생육이 저하될 수 있고, 발효 기간이 8일 미만일 경우 발효가 충분하지 않아 생리활성물질 등의 생성이 저조하게 될 수 있으며, 12일을 초과한 경우는 과발효에 의해 생리활성물질이 분해될 수 있다.If the amount of Hong Guo Mung bean inoculation is less than 3% (v/w), the fermentation rate may be delayed, and if it exceeds 10% (v/w), the mycelial growth rate may be fast and the conversion rate may be low, and if the fermentation temperature is less than 20℃, the fermentation period may be long, which may lead to contamination by various bacteria, and if it exceeds 30℃, the growth of mycelia may be reduced, and if the fermentation period is less than 8 days, fermentation may not be sufficient, resulting in low production of physiologically active substances, and if it exceeds 12 days, the physiologically active substances may be decomposed due to overfermentation.
본 발명에서 산양삼새싹 및 콩의 혼합물은 발효 전에, 5~10배(v/v)의 물을 첨가하여 5~8시간 수화시켜 수분이 40~50% 정도 되게 조정한 후 100~120℃ 이상에서 30~60분 증자처리하는 것이 바람직하다. 가장 바람직하게는 120℃에서 30분 증자한다. In the present invention, it is preferable to add 5 to 10 times (v/v) of water to the mixture of wild ginseng sprouts and soybeans before fermentation, hydrate them for 5 to 8 hours to adjust the moisture content to about 40 to 50%, and then steam them at 100 to 120°C or higher for 30 to 60 minutes. It is most preferable to steam them at 120°C for 30 minutes.
본 발명에서 수화 처리 시 수분 함량이 40% 이하의 홍국균 균사 생육이 원활하지 않으며, 수분 함량이 50% 이상의 경우 홍국균 균사 생육뿐만 아니라 세균 등의 증식이 이루어질 수 있다. 한편, 증자 처리 시 30분 이하 처리 시 살균이 완벽하게 이루어지 않아 홍국균 균사 이외에 세균 등의 증식에 의하여 이상발효가 진행될 수 있고 60분 이상 처리 시 영양성분 파괴되는 과다하게 진행될 수 있다.In the present invention, when the moisture content is 40% or less during the hydration treatment, the growth of the Hong Aspergillus mycelia is not smooth, and when the moisture content is 50% or more, not only the growth of the Hong Aspergillus mycelia but also the proliferation of bacteria may occur. On the other hand, when the steaming treatment is performed for less than 30 minutes, sterilization is not completely achieved, and abnormal fermentation may proceed due to the proliferation of bacteria in addition to the Hong Aspergillus mycelia, and when the treatment is performed for more than 60 minutes, the fermentation may proceed excessively, destroying nutrients.
본 발명에 따른 산양삼새싹의 홍국균 발효조성물은 진세노사이드 Rg2를 1.34 mg/g 이상, F1을 1.3 mg/g 이상, 프로토파낙사트리올을 0.22 mg/g 이상, Rd를 5.63 mg/g 이상, Rd2를 1.18 mg/g 이상, F2를 3.25 mg/g 이상, Rg3를 1.15 mg/g 이상 및 프로토파낙사디올을 14.6 mg/g 이상 함유한다 (표 1). The fermented composition of wild ginseng sprouts according to the present invention contains ginsenoside Rg2 of 1.34 mg/g or more, F1 of 1.3 mg/g or more, protopanaxadiol of 0.22 mg/g or more, Rd of 5.63 mg/g or more, Rd2 of 1.18 mg/g or more, F2 of 3.25 mg/g or more, Rg3 of 1.15 mg/g or more, and protopanaxadiol of 14.6 mg/g or more (Table 1).
본 발명에 따른 산양삼새싹의 홍국균 발효조성물은 진세노사이드 Rg2, F1, 프로토파낙사트리올, Rd, Rd2, F2, Rg3 및 프로토파낙사디올의 함량이 가공전 혼합물(비교예 1)에 비하여 각각 약 2.8배 이상, 1.6배 이상, 2.4배 이상, 2.1배 이상, 3.2배 이상, 4.2배 이상, 6.7배 이상 및 약 7.9배 이상 증진된다 (표 1). The fermented composition of wild ginseng sprouts according to the present invention has contents of ginsenosides Rg2, F1, protopanaxatriol, Rd, Rd2, F2, Rg3 and protopanaxadiol increased by about 2.8 times or more, 1.6 times or more, 2.4 times or more, 2.1 times or more, 3.2 times or more, 4.2 times or more, 6.7 times or more and about 7.9 times or more, respectively, compared to the mixture before processing (Comparative Example 1) (Table 1).
본 발명에 따른 산양삼새싹의 홍국균 발효조성물에서 프로토파낙사트리올 계열, 프로토파낙사디올 계열, 및 총 진세노사이드 함량은 각각 2.98 mg/g 이상, 25.81 mg/g 이상, 및 28.79 mg/g 이상 함유된다 (도 3). In the fermented composition of wild ginseng sprouts according to the present invention, the contents of protopanaxatriol series, protopanaxadiol series, and total ginsenosides are 2.98 mg/g or more, 25.81 mg/g or more, and 28.79 mg/g or more, respectively (Fig. 3).
본 발명에 따른 산양삼새싹의 홍국균 발효조성물은 프로토파낙사트리올 계열, 프로토파낙사디올 계열 및 총 진세노사이드의 함량이 가공전 혼합물(비교예 1)에 비하여 각각 약 2.3배 이상, 4.5배 이상, 및 4.1배 이상 증진된다 (도 3). The fermented composition of wild ginseng sprouts according to the present invention increases the contents of protopanaxatriol series, protopanaxadiol series, and total ginsenosides by about 2.3 times or more, 4.5 times or more, and 4.1 times or more, respectively, compared to the mixture before processing (Comparative Example 1) (Fig. 3).
또한 본 발명에 따른 산양삼새싹의 홍국균 발효조성물은 진세노사이드 Rg2, F1, 프로토파낙사트리올, Rd, Rd2, F1, Rg3, 및 프로토파낙사디올, 총 페놀릭스 및 총 플라보노이드 등의 생리활성물질의 함량이 강화되어, 증진된 항산화 활성, 항당뇨 활성 및 항비만 활성을 갖는다 (표 1 ~ 표 2, 도 3 및 도 4 ~ 8).In addition, the fermented composition of wild ginseng sprouts according to the present invention has enhanced contents of physiologically active substances such as ginsenosides Rg2, F1, protopanaxatriol, Rd, Rd2, F1, Rg3, and protopanaxadiol, total phenolics and total flavonoids, thereby having enhanced antioxidant activity, antidiabetic activity and antiobesity activity (Tables 1 to 2, Figs. 3 and 4 to 8).
본 발명의 또 다른 목적을 달성하기 위하여, 본 발명은 산양삼새싹 및 콩의 혼합물을 홍국균으로 발효하여 진세노사이드 Rg2, F1, 프로토파낙사트리올, Rd, Rd2, F1, Rg3, 및 프로토파낙사디올이 증진된 산양삼의 홍국균 발효조성물의 제조방법을 제공한다. In order to achieve another object of the present invention, the present invention provides a method for producing a fermented composition of wild ginseng and Hong Aspergillus oryzae by fermenting a mixture of wild ginseng sprouts and soybeans with Hong Aspergillus oryzae, wherein ginsenosides Rg2, F1, protopanaxatriol, Rd, Rd2, F1, Rg3, and protopanaxadiol are increased.
구체적으로 상기 방법은 Specifically, the above method
ⅰ) 산양삼새싹 90~96 중량% 및 콩 6~10 중량%를 혼합한 후 물을 5~10배(v/w)으로 혼합하여 5~7시간 수화하는 단계;i) A step of mixing 90 to 96 wt% of wild ginseng sprouts and 6 to 10 wt% of soybeans, then mixing with water in a ratio of 5 to 10 times (v/w) and hydrating for 5 to 7 hours;
ⅱ) 100~120℃에서 30~60분 증자하는 단계; 및 ⅱ) Steaming step at 100~120℃ for 30~60 minutes; and
ⅲ) 홍국균을 3~10%(v/w) 농도로 접종하여 20~30℃에서 8~12일간 발효하는 단계를 포함한다.ⅲ) It includes a step of inoculating Honggukgyun at a concentration of 3 to 10% (v/w) and fermenting at 20 to 30°C for 8 to 12 days.
본 발명의 제조방법에서, 산양삼새싹 및 콩의 혼합물의 중량비, 수화, 증자, 홍국균 및 발효는 상기에서 정의된 바와 같다. In the manufacturing method of the present invention, the weight ratio of the mixture of wild ginseng sprouts and soybeans, hydration, steaming, red yeast and fermentation are as defined above.
홍국균 원활한 발효를 위하여 발효 전에 산양삼새싹 및 콩의 혼합물에 물을 첨가하여 수화할 수 있다.To ensure smooth fermentation, water can be added to the mixture of wild ginseng sprouts and soybeans before fermentation to hydrate them.
발효 전에, 살균하기 위하여 증자 처리될 수 있다. 증자는 100~120℃ 이상에서 30 ~ 60분 증자하는 것이 바람직하고, 가장 바람직하게는 120℃에서 30분 증자한다. Before fermentation, it can be steamed to sterilize. It is preferable to steam at 100~120℃ or higher for 30~60 minutes, and most preferably at 120℃ for 30 minutes.
본 발명의 또 다른 목적에 따라서, 본 발명은 상기 제조방법에 의해 제조된 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹 홍국균 발효조성물을 포함하는 기능성식품을 제공한다. According to another object of the present invention, the present invention provides a functional food comprising a fermented composition of wild ginseng sprouts and Hong Guk-myun, which is produced by the above-mentioned production method and has increased ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명에 따른 기능성식품은 우수한 항산화 활성, 당뇨 개선 및 비만 개선 효과를 갖는다 (도 4a~도 6). The functional food according to the present invention has excellent antioxidant activity, diabetes improvement, and obesity improvement effects (Figs. 4a to 6).
본 발명의 또 다른 목적에 따라서, 진세노사이드 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 증진된 산양삼새싹 홍국균 발효조성물을 포함하는 화장품을 제공한다.According to another object of the present invention, a cosmetic is provided which includes a fermented composition of wild ginseng sprouts and Hong Guk-myun having enhanced ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol.
본 발명의 식품 또는 화장품은 본 발명의 발효조성물 또는 이의 추출물을 그대로 첨가하거나 다른 식품 성분과 혼합되어 제조될 수 있고, 통상적인 방법에 따라 적절하게 제조될 수 있다.The food or cosmetic of the present invention can be manufactured by adding the fermented composition of the present invention or its extract as is or by mixing it with other food ingredients, and can be manufactured appropriately according to a conventional method.
본 발명에서 상기 식품의 종류는 특별히 제한되지 않으며, 환제, 정제, 캡슐제, 발효차, 발효식품 (김치류, 피클류 등), 발효음료 (파우치제, 드링크제 등) 등일 수 있으나, 이에 제한되지는 않는다. 화장품의 종류는 마스크팩, 스킨, 로션, 크림 등일 수 있으나, 이에 제한되지는 않는다. In the present invention, the type of the food is not particularly limited, and may include, but is not limited to, pills, tablets, capsules, fermented tea, fermented foods (kimchi, pickles, etc.), fermented beverages (pouches, drinks, etc.). The type of cosmetics may include, but is not limited to, mask packs, skins, lotions, creams, etc.
본 발명에 따른 산양삼새싹 홍국균 발효조성물은 진세노사이드 Rg2, F1, Rd, Rd2, F2, Rg3, 프로토파낙사트리올 및 프로토파낙사디올이 고함량으로 함유되어 기능성식품 및 화장품의 소재로 사용될 수 있다.The fermented composition of wild ginseng sprouts and Honggukgyun according to the present invention contains high contents of ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, and can be used as a material for functional foods and cosmetics.
또한 본 발명에 따른 기능성식품 또는 화장품은 진세노사이드 Rg2, Rg3 F1, F2, Rd, Rd2, 프로토파낙사트리올 및 프로토파낙사디올의 함량이 높으며, 더불어 우수한 항산화 활성, 알파-글루코시다아제 저해활성 및 췌장-리파아제 저해활성을 가져서, 지방생성 억제효과, 체중 조절, 콜레스테롤 저하, 고지혈증 개선, 동맥경화 완화, 당뇨병 개선, 비만 개선, 혈액순환 개선, 면역력 개선, 피부 미용, 여성 갱년기 증후군 개선용으로 유용하다. In addition, the functional food or cosmetic according to the present invention has a high content of ginsenoside Rg2, Rg3 F1, F2, Rd, Rd2, protopanaxatriol and protopanaxadiol, and further has excellent antioxidant activity, alpha-glucosidase inhibitory activity and pancreatic lipase inhibitory activity, and is useful for suppressing fat production, controlling weight, lowering cholesterol, improving hyperlipidemia, alleviating arteriosclerosis, improving diabetes, improving obesity, improving blood circulation, improving immunity, beautifying skin and improving female menopausal syndrome.
도 1은 본 발명의 홍국균 발효조성물의 제조 공정도의 일례이다.
도 2는 진세노사이드 HPLC 크로마토그램을 나타낸 것이다. (A)는 비교예인 산양삼새싹 원료의 진세노사이드 HPLC 크로마토그램이며, (B)는 실시예 1인 모나스커스 퍼프레우스의 발효조성물의 진세노사이드 HPLC 크로마토그램이며, (C)는 실시예 2인 모나스커스 필로서스의 발효조성물의 진세노사이드 HPLC 크로마토그램이다.
도 3은 본 발명에 따른 발효조성물의 프로토파낙사트리올 계열, 프로토파낙사디올 계열, 및 총 진세노사이드 함량을 나타낸 것이다.
도 4는 본 발명에 따른 발효조성물의 DPPH 라디칼 소거활성을 나타낸 것이다,
도 5는 본 발명에 따른 발효조성물의 ABTS 라디칼 소거활성을 나타낸 것이다.
도 6은 본 발명에 따른 발효조성물의 환원력(FRAP)을 나타낸 것이다.
도 7은 본 발명에 따른 발효조성물의 알파-글루코시다아제 저해활성을 나타낸 것이다.
도 8은 본 발명에 따른 발효조성물의 췌장-리파아제 저해활성을 나타낸 것이다.Figure 1 is an example of a manufacturing process diagram of the fermented composition of Honggukgyun of the present invention.
Figure 2 shows ginsenoside HPLC chromatograms. (A) is the ginsenoside HPLC chromatogram of the wild ginseng sprout raw material as a comparative example, (B) is the ginsenoside HPLC chromatogram of the fermented composition of Monascus perpreus as Example 1, and (C) is the ginsenoside HPLC chromatogram of the fermented composition of Monascus piloseus as Example 2.
Figure 3 shows the contents of protopanaxatriol series, protopanaxadiol series, and total ginsenoside of the fermented composition according to the present invention.
Figure 4 shows the DPPH radical scavenging activity of the fermentation composition according to the present invention.
Figure 5 shows the ABTS radical scavenging activity of the fermentation composition according to the present invention.
Figure 6 shows the reducing power (FRAP) of the fermentation composition according to the present invention.
Figure 7 shows the alpha-glucosidase inhibitory activity of the fermentation composition according to the present invention.
Figure 8 shows the pancreatic lipase inhibitory activity of the fermented composition according to the present invention.
다음의 실시예들에 의해 본 발명이 더 상세히 설명된다. 이들 실시예는 본 발명을 예시하기 위한 것이며, 본 발명의 범위가 이들에 의해 제한되어서는 안된다.The present invention is further described in detail by the following examples. These examples are intended to illustrate the present invention, and the scope of the present invention should not be limited by them.
제조예 1: 발효조성물 제조Manufacturing Example 1: Manufacturing of fermentation composition
산양삼새싹은 2020년도 함양군 백전면 일대에서 재배된 것을 농업회사법인 주식회사 진생바이오로로부터 공급받아 사용하였다. 콩(오리알태콩)은 진주시 소재 대형마트에서 구입하여 사용하였다.The wild ginseng sprouts were grown in the Baekjeon-myeon area of Hamyang-gun in 2020 and supplied by Jinseong Bio, an agricultural corporation. The soybeans (orial-tae soybeans) were purchased from a large mart in Jinju-si.
훙국균은 한국미생물보존센터로부터 모나스커스 필로서스(Monascus pilosus) 및 모나스커스 퍼프레우스(Monascus purpureus)를 분양받아 활성화시켜 사용하였다. 훙국균 계대 배양은 Potato Dextrose broth/agar(PDB/PDA, BD-Difco사, Sparks, MD, USA)를 사용하였다. Monascus pilosus and Monascus purpureus were obtained from the Korean Microbiological Conservation Center and used after activation. Potato Dextrose broth/agar (PDB/PDA, BD-Difco, Sparks, MD, USA) was used for the subculture of Monascus.
산양삼새싹은 흐르는 물에 3회 세척한 후 약 1 cm 정도로 절단한 후 55℃에서 3일간 건조하여 준비하였다. 건조 산양삼과 콩을 9:1의 중량비로 혼합하여 산양삼새싹 혼합시료를 준비하였다.The wild ginseng sprouts were washed three times in running water, cut into approximately 1 cm pieces, and dried at 55°C for 3 days to prepare them. A wild ginseng sprout mixture sample was prepared by mixing dried wild ginseng and soybeans in a weight ratio of 9:1.
산양삼새싹 혼합시료에 10배(v/w) 정제수를 첨가하고 6시간 수화시켜 수분 함량을 약 40% 정도 되게 조정한 후 고압멸균기를 이용하여 120℃에서 30분 동안 증자 처리하고 홍국균 배양액을 5%(v/w) 접종한 뒤 25℃에서 10일간 발효를 진행하여 발효조성물을 얻었다 (실시예 1 (모나스커스 필로서스로 발효), 실시예 2 (모나스커스 퍼프레우스 발효); 도 1). A 10-fold (v/w) volume of purified water was added to a mixed sample of wild ginseng sprouts, and the mixture was hydrated for 6 hours to adjust the moisture content to approximately 40%. The mixture was steamed at 120°C for 30 minutes using an autoclave, and 5% (v/w) of a culture of Hong Guo Myeong was inoculated. Fermentation was performed at 25°C for 10 days to obtain a fermented composition (Example 1 (Fermentation with Monascus phyllosus), Example 2 (Fermentation with Monascus perpreus); Fig. 1).
비교를 위하여, 건조 산양삼새싹과 콩을 9:1의 중량비로 혼합하여 산양삼새싹 혼합시료 조성물(비교예)을 준비하였다.For comparison, a mixed sample composition of dried wild ginseng sprouts (comparative example) was prepared by mixing dried wild ginseng sprouts and soybeans in a weight ratio of 9:1.
참조예: 분석시료Reference example: Analysis sample
실시예 1 및 실시예 2의 발효조성물, 비교예 1의 조성물을 각각 55℃에서 3일간 건조하여 분쇄시켜 분말 시료를 준비하였다. The fermentation compositions of Examples 1 and 2 and the composition of Comparative Example 1 were each dried at 55°C for 3 days and pulverized to prepare powder samples.
분말 시료 1 g에 50% 메탄올을 20배 첨가하여 12시간 동안 추출한 완전히 농축한 후 50% 메탄올을 2 ml을 첨가하여 녹인 후 0.45 μm 여과 필터로 여과하여 HPLC 베일에 담아 진세노사이드를 분석하였다. 1 g of powdered sample was extracted for 12 hours by adding 20 times 50% methanol, completely concentrated, dissolved by adding 2 ml of 50% methanol, filtered through a 0.45 μm filter, and placed in an HPLC bale to analyze ginsenosides.
분말 시료 10 g에 50% 주정을 20배 첨가하여 12시간 동안 추출한 일부 0.45 μm 여과 필터로 여과하여 총 페놀릭스와 총 플라보노이드 분석에 사용하였고 나머지 추출액은 감압여과기를 이용해 여과하고 감압농축기를 이용하여 완전 농축시킨 후 동결건조기(FD-1000, Tokyo, Rikakikai, Japan)를 이용하여 동결건조하였다. 최종 동결건조된 시료에 50% 주정을 첨가하여 시료농도가 0.25, 0.5, 1.0 및 2.0 mg/mL이 되게 제조한 후 하기 생리활성시험에 사용하였다.A portion of the 10 g of powdered sample, extracted for 12 hours by adding 20 times 50% alcohol, was filtered through a 0.45 μm filter and used for total phenolics and total flavonoids analysis. The remaining extract was filtered using a vacuum filter, completely concentrated using a vacuum evaporator, and then freeze-dried using a freeze-dryer (FD-1000, Tokyo, Rikakikai, Japan). 50% alcohol was added to the final freeze-dried sample to prepare sample concentrations of 0.25, 0.5, 1.0, and 2.0 mg/mL, which were then used in the following physiological activity test.
시험예 1: 진세노사이드 함량 분석Test Example 1: Analysis of Ginsenoside Content
진세노사이드 분석은 기능성식품분석법의 홍삼 사포닌 분석법에 기술된 방법을 변형하여 고압액체크로마토그래피(HPLC, high press liquid chromatograph)로 분석하였다. 분석 컬럼은 TSKgel ODS-100Z을 사용하여 시료주입량 10 ㎕, 온도는 30℃, 측정파장은 203 nm, 유속은 1.0 ㎖/min으로 하였고 이동상으로는 A용액은 HPLC water, B용액은 아세토니트릴을 사용하였다. HPLC 분석 조건은 이동상 용액은 0분때 A용액 81% : B용액 19%로 흘려주고 15분때에는 A용액 80% : B용액 20%로 흘려주고 40분때 A용액 77% : B용액 23%, 40분때 A용액 77% : B용액 23%, 42분때 A용액 70% : B용액 30%, 75분때에 A용액 65% : B용액 35%, 80분때에 A용액 30% : B용액 70%, 90분때에 A용액 10% : B용액 90%로 이동상을 흘려주었다. 실시예 1, 실시예 2 및 비교예의 진세노사이드 HPLC 크로마토그램을 도 2에 나타냈고, 분석된 진세노사이드 Rg2, Rg3 F1, F2, Rd, Rd2, 프로토파낙사트리올(PPT) 및 프로토파낙사디올(PPD) 함량을 각각 표 1에 나타내었다. 또한 프로토파낙사트리올 계열(Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량을 산출하여 도 3에 나타냈다. Ginsenoside analysis was performed by high pressure liquid chromatography (HPLC) using a modified method described in the red ginseng saponin analysis method of the functional food analysis method. The analysis column used was TSKgel ODS-100Z, the sample injection amount was 10 ㎕, the temperature was 30℃, the measurement wavelength was 203 nm, and the flow rate was 1.0 ㎖/min. HPLC water was used as the mobile phase for Solution A and acetonitrile for Solution B. The HPLC analysis conditions were as follows: at 0 min, 81% solution A : 19% solution B was flowed, at 15 min, 80% solution A : 20% solution B was flowed, at 40 min, 77% solution A : 23% solution B, at 40 min, 77% solution A : 23% solution B, at 42 min, 70% solution A : 30% solution B, at 75 min, 65% solution A : 35% solution B, at 80 min, 30% solution A : 70% solution B, and at 90 min, 10% solution A : 90% solution B. The HPLC chromatograms of ginsenosides of Examples 1, 2, and Comparative Examples are shown in Fig. 2, and the contents of the analyzed ginsenosides Rg2, Rg3 F1, F2, Rd, Rd2, protopanaxadiol (PPT), and protopanaxadiol (PPD) are respectively shown in Table 1. In addition, the contents of protopanaxadiol series (Rg2, F1, and PPT) ginsenosides, protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides, and total ginsenosides were calculated and shown in Fig. 3.
(원료)Comparative Example 1
(raw material)
(홍국균-1)Example 1
(Hong Guk-gyun-1)
(홍국균-2)Example 2
(Hong Guk-gyun-2)
홍국균-2: 모나스커스 필로서스(Monascus piolsus).
모든 실험은 5반복 진행하여 평균값으로 표시함.Hong Guk-gyun-1: Monascus purpureus .
Hong Guk-gyun-2: Monascus piolsus .
All experiments were repeated five times and the average value was displayed.
도 2에 나타낸 바와 같이, 비교예 1의 조성물에서는 Rg2, Rg3 F1, F2, Rd, Rd2, 프로토파낙사트리올 및 프로토파낙사디올 피크가 낮게 나타난 반면에, 본 발명에 따른 실시예 1의 모나스커스 필로서스 발효조성물 및 실시예 2의 모나스커스 퍼프레우스 발효조성물에서는 Rg2, Rg3 F1, F2, Rd, Rd2, 프로토파낙사트리올 및 프로토파낙사디올 피크가 현저히 높아진 것을 확인할 수 있다. As shown in FIG. 2, in the composition of Comparative Example 1, the Rg2, Rg3 F1, F2, Rd, Rd2, protopanaxatriol and protopanaxadiol peaks were low, whereas in the Monascus phyllosus fermentation composition of Example 1 and the Monascus perpreus fermentation composition of Example 2 according to the present invention, it can be confirmed that the Rg2, Rg3 F1, F2, Rd, Rd2, protopanaxatriol and protopanaxadiol peaks were significantly high.
또한, 표 1에 나타낸 바와 같이, 가공되지 않은 산양삼새싹 혼합원료인 비교예 1의 Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD 함량은 각각 0.48 mg/g, 0.66 mg/g, 0.14 mg/g, 2.65 mg/g, 0.37 mg/g, 0.77 mg/g, 0.17 mg/g, 및 1.84 mg/g이며, 실시예 1의 모나스커스 필로서스 발효조성물의 Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD 함량은 각각 1.37 mg/g, 1.78 mg/g, 0.22 mg/g, 8.08 mg/g, 1.32 mg/g, 3.49 mg/g, 1.40 mg/g, 및 16.18 mg/g로 각각 약 2.9배, 2.7배, 1.6배, 3.0배, 3.6배, 4.5배, 8.2배, 및 8.8배 증가하였고, 실시예 2의 모나스커스 퍼프레우스 발효조성물의 Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD 함량은 각각 1.34 mg/g, 1.30 mg/g, 0.34 mg/g, 5.63 mg/g, 1.18 mg/g, 3.25 mg/g, 1.15 mg/g, 및 14.60 mg/g로 각각 약 2.8배, 2.0배, 2.4배, 2.1배, 3.2배, 4.2배, 6.7배, 및 7.9배 증가됨을 확인할 수 있다.In addition, as shown in Table 1, the Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD contents of the unprocessed wild ginseng sprout mixed raw material of Comparative Example 1 are 0.48 mg/g, 0.66 mg/g, 0.14 mg/g, 2.65 mg/g, 0.37 mg/g, 0.77 mg/g, 0.17 mg/g, and 1.84 mg/g, respectively, and the Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD contents of the Monascus phyllosus fermented composition of Example 1 are 1.37 mg/g, 1.78 mg/g, 0.22 mg/g, 8.08 mg/g, 1.32 mg/g, 3.49 mg/g, 1.40 mg/g, and The contents of the Monascus perpreus fermented composition of Example 2 increased by about 2.9 times, 2.7 times, 1.6 times, 3.0 times, 3.6 times, 4.5 times, 8.2 times, and 8.8 times, respectively, to 16.18 mg/g, and the Rg2, F1, PPT, Rd, Rd2, F2, Rg3, and PPD contents of the Monascus perpreus fermented composition of Example 2 increased by about 2.8 times, 2.0 times, 2.4 times, 2.1 times, 3.2 times, 4.2 times, 6.7 times, and 7.9 times, respectively, to 1.34 mg/g, 1.30 mg/g, 0.34 mg/g, 5.63 mg/g, 1.18 mg/g, 3.25 mg/g, 1.15 mg/g, and 14.60 mg/g.
도 3에 도시된 바와 같이, 가공되지 않은 산양산 혼합원료인 비교예 1의 프로토파낙사트리올 계열(Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량은 각각 1.28 mg/g, 5.80 mg/g, 및 7.08 mg/g이며, 실시예 1의 모나스커스 필로서스 발효조성물의 프로토파낙사트리올 계열(Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량은 각각 3.37 mg/g, 30.47 mg/g, 및 33.84 mg/g으로 약 2.6배, 5.3배, 및 4.8배 증가하였으며, 실시예 2의 모나스커스 퍼프레우스 발효조성물의 프로토파낙사트리올 계열(Rg2, F1, 및 PPT) 진세노사이드, 프로토파낙사디올 계열(Rd, Rd2, F2, Rg3, 및 PPD) 진세노사이드, 및 총 진세노사이드 함량은 각각 2.98 mg/g, 25.81 mg/g, 및 28.79 mg/g으로 약 2.3배, 4.5배, 및 4.1배 증가됨을 확인할 수 있었다.As shown in FIG. 3, the contents of protopanaxatriol series (Rg2, F1, and PPT) ginsenosides, protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides, and total ginsenosides of Comparative Example 1, which is an unprocessed mixed raw material of wild ginseng, are 1.28 mg/g, 5.80 mg/g, and 7.08 mg/g, respectively, and the contents of protopanaxatriol series (Rg2, F1, and PPT) ginsenosides, protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides, and total ginsenosides of the fermented composition of Monascus phyllosus of Example 1 are 3.37 mg/g, 30.47 mg/g, and 33.84 mg/g, respectively, which are about 2.6 times, 5.3 times, and The contents of protopanaxadiol series (Rd, Rd2, F2, Rg3, and PPD) ginsenosides, and total ginsenosides of the Monascus perpreus fermented composition of Example 2 were 2.98 mg/g, 25.81 mg/g, and 28.79 mg/g, respectively, indicating an increase of about 2.3 times, 4.5 times, and 4.1 times.
따라서 홍국균으로 발효된 본 발명에 따른 산양삼새싹 발효조성물은 진세노사이드 Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD의 함량이 현저히 강화됨을 알 수 있다. Therefore, it can be seen that the fermented composition of wild ginseng sprouts according to the present invention fermented with Honggukgyun has significantly enhanced contents of ginsenosides Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD.
시험예 2. 생리활성성분 함량 분석Test Example 2. Analysis of the content of physiologically active ingredients
항산화 활성 등을 나타내는 생리활성성분인 총 페놀릭스 및 총 플라보노이드스 함량 함량을 분석하였다.The content of total phenolics and total flavonoids, which are physiologically active components exhibiting antioxidant activity, were analyzed.
<총 페놀릭스 함량><Total phenol content>
분석시료를 시험관에 0.5 ml 분주하고 여기에 25% Na2CO3 용액 0.5 ml를 첨가하여 3분간 정치시킨 후, 2N Folin-Ciocalteu 페놀 시약 0.25 ml를 첨가하여 혼합한 다음 30℃에서 1시간 동안 정치시킨 후 750 nm에서 분광광도계를 사용하여 750nm에서 흡광도를 측정하였다. 이때 총 페놀릭스 함량은 갈산(Gallic acid)을 이용하여 작성한 표준곡선으로부터 함량을 구하여 갈산에 상당하는 양으로 계산하였고 그 결과를 표 2에 나타냈다.The analysis sample was dispensed (0.5 ml) into a test tube, to which 0.5 ml of 25% Na 2 CO 3 solution was added, allowed to stand for 3 minutes, 0.25 ml of 2N Folin-Ciocalteu phenol reagent was added and mixed, allowed to stand for 1 hour at 30°C, and then the absorbance was measured at 750 nm using a spectrophotometer. At this time, the total phenolix content was calculated as the amount equivalent to gallic acid by obtaining the content from a standard curve created using gallic acid, and the results are shown in Table 2.
표 2에 나타낸 바와 같이, 총 페놀릭스 함량은 비교예 1에서는 3.28 mg/g이었으며, 실시예 1에서는 5.50 mg/g으로 나타났고, 실시예 2에서는 4.85 mg/g 나타나, 본 발명에 따른 발효조성물은 총 페놀릭스 함량이 증진됨을 확인할 수 있다. As shown in Table 2, the total phenol content was 3.28 mg/g in Comparative Example 1, 5.50 mg/g in Example 1, and 4.85 mg/g in Example 2, confirming that the fermented composition according to the present invention has an increased total phenol content.
(원료)Comparative Example 1
(raw material)
(홍국균-1)Example 1
(Hong Guk-gyun-1)
(홍국균-2)Example 2
(Hong Guk-gyun-2)
홍국균-2: 모나스커스 필로서스(Monascus piolsus).
모든 실험은 5반복 진행하여 평균값으로 표시함.Hong Guk-gyun-1: Monascus purpureus .
Hong Guk-gyun-2: Monascus piolsus .
All experiments were repeated five times and the average value was displayed.
<총 플라보노이드 함량><Total flavonoid content>
분석시료 0.5 ml에 디에틸렌글리콜 1.0 ml를 분주한 후 1 N NaOH 0.01 ml를 첨가한 후 하여 37℃ 항온수조에서 1시간 방치 후 420 nm에서 분광광도계로 흡광도를 측정하였다. 이때 총 플라보노이드스 함량은 루틴(rutin)을 이용하여 작성한 표준곡선으로부터 함량을 구하였고 그 결과는 표 2에 나타내었다. After dispensing 1.0 ml of diethylene glycol to 0.5 ml of the analysis sample, 0.01 ml of 1 N NaOH was added, and the sample was left in a constant temperature water bath at 37°C for 1 hour. The absorbance was measured at 420 nm using a spectrophotometer. At this time, the total flavonoid content was obtained from a standard curve created using rutin, and the results are shown in Table 2.
표 2에 나타낸 바와 같이, 총 플라보노이드 함량도, 비교예 1, 실시예 1 및 실시예 2에서 각각 1.36 mg/g, 2.86 mg/g, 및 2.75 mg/g으로 나타나, 본 발명에 따른 발효조성물은 총 플라보노이드스의 함량도 크게 증가하는 것을 확인할 수 있다.As shown in Table 2, the total flavonoid contents were 1.36 mg/g, 2.86 mg/g, and 2.75 mg/g in Comparative Example 1, Example 1, and Example 2, respectively, confirming that the fermented composition according to the present invention significantly increases the total flavonoid content.
시험예 3. 항산화 활성 분석Test Example 3. Antioxidant Activity Analysis
항산화 활성은 DPPH 라디칼 소거활성, ABTS 라디칼 소거활성, 및 FRAP 환원력을 측정하여 분석하였다.Antioxidant activity was analyzed by measuring DPPH radical scavenging activity, ABTS radical scavenging activity, and FRAP reducing power.
참고예에서와 같이 실시예 1, 실시예 2 및 비교예 1의 분석시료를 0.25, 0.5, 1, 및 2 mg/ml 농도로 제조하여 사용하였다.As in the reference example, the analysis samples of Example 1, Example 2, and Comparative Example 1 were prepared and used at concentrations of 0.25, 0.5, 1, and 2 mg/ml.
<DPPH 라디칼 소거활성><DPPH radical scavenging activity>
각각의 시료 0.2 ml에 DPPH 메탄올 용액(1.5×10-4 M) 0.8 ml를 첨가하여 10초간 교반후 암실에서 30분간 방치한 후 525 nm에서 흡광도를 측정하여 수행하였다. DPPH 라디칼 소거활성의 음성 대조구는 시료 대신 추출용매를 사용하여 동일한 방법으로 진행하여 흡광도의 차이를 다음과 같은 식에 의해 백분율(%)로 산출하였으며, 그 결과를 도 4에 도시하였다. Each sample (0.2 ml) was added with 0.8 ml of DPPH methanol solution (1.5×10 -4 M), stirred for 10 seconds, left in a dark room for 30 minutes, and then the absorbance was measured at 525 nm. The negative control group of DPPH radical scavenging activity was performed in the same manner using an extraction solvent instead of the sample, and the difference in absorbance was calculated as a percentage (%) by the following formula, and the results are shown in Fig. 4.
라디칼 소거활성(%) = [1-(음성대조구 흡광도 ÷실험구 흡광도)] ×100Radical scavenging activity (%) = [1-(absorbance of negative control group ÷ absorbance of experimental group)] × 100
도 4에 나타난 바와 같이, DPPH 라디칼 소거활성은 1 mg/ml의 농도에서 비교예 1, 실시예 1 및 실시예 2는 각각 17.81%, 66.89%, 및 64.03%의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 활성을 보였다. As shown in Fig. 4, the DPPH radical scavenging activity of Comparative Example 1, Example 1, and Example 2 at a concentration of 1 mg/ml was 17.81%, 66.89%, and 64.03%, respectively, indicating that the fermented compositions of Example 1 and Example 2 exhibited significantly higher activity.
<ABTS 라디칼 소거활성><ABTS radical scavenging activity>
7 mM ABTS+와 2.45 mM K2S2O8를 1:1 비율로 섞어 암실에서 12~16시간 반응시킨 후 메탄올과 1:88 비율로 섞어 732 nm에서 대조구의 흡광도 값이 0.7±0.02가 되도록 조절한 ABTS+ 용액을 사용하였다. 각각의 시료 0.1 ml와 ABTS+ 용액 0.9 ml를 첨가하여 혼합한 후 3분간 정치 후 즉시 732 nm에서 분광광도계를 사용하여 흡광도를 측정하였다. 음성대조구 실험은 시료 대신에 추출용매를 취하여 진행하였으며 실험구와 음성 대조구의 흡광도를 구하여 상기 식에 의해 백분율(%)로 산출하여 그 결과를 도 5에 나타냈다. 7 mM ABTS + and 2.45 mM K 2 S 2 O 8 were mixed in a 1:1 ratio and reacted in a darkroom for 12 to 16 hours, then mixed with methanol in a 1:88 ratio to adjust the absorbance value of the control group to 0.7±0.02 at 732 nm. 0.1 ml of each sample and 0.9 ml of ABTS + solution were added and mixed, and after standing for 3 minutes, the absorbance was immediately measured using a spectrophotometer at 732 nm. The negative control experiment was conducted by taking an extraction solvent instead of the sample, and the absorbance of the experimental group and the negative control group was calculated as a percentage (%) using the above formula, and the results are shown in Fig. 5.
도 5에 나타난 바와 같이, ABTS 라디칼 소거활성은 0.5 mg/ml의 농도에서 비교예 1, 실시예 1 및 실시예 2는 각각 32.93%, 78.16%, 및 72.24%의 활성을 나타내 실시예 1 및 실시예 2의 발효조성물이 현저히 높은 활성을 보였다.As shown in Fig. 5, ABTS radical scavenging activity was 32.93%, 78.16%, and 72.24% for Comparative Example 1, Example 1, and Example 2, respectively, at a concentration of 0.5 mg/ml, indicating that the fermentation compositions of Example 1 and Example 2 exhibited significantly higher activity.
<FRAP 환원력 분석><FRAP Reduction Power Analysis>
FRAP 환원력 분석에서 반응액으로는 30 mM 아세테이트 완충액(pH 3.6), 40 mM 염산에 녹인 10 mM 2,4,6-트리피리딜-s-트리아진(TPTZ, T1253, C18H12N6, MW312.33) 및 20 mM FeCl3(F7134, MW 162.20, in DW)를 준비하였으며, 아세테이트 완충액, TPTZ 용액 및 FeCl3 용액을 10:1:1 (v/v/v)로 혼합하여 37 ℃에서 15분간 예비반응을 시켜두었다. 각각의 시료 0.05 ml에 FRAP 시약 0.95ml를 첨가하여 37 ℃에서 약 15분간 반응시키고 590 nm에서 흡광도를 측정하여 그 결과를 도 6에 나타냈다.In the FRAP reducing power analysis, 10 mM 2,4,6-tripyridyl-s-triazine (TPTZ, T1253, C 18 H 12 N 6 , MW312.33) and 20 mM FeCl 3 (F7134, MW 162.20, in DW) dissolved in 30 mM acetate buffer (pH 3.6) and 40 mM hydrochloric acid were prepared as the reaction solution. The acetate buffer, TPTZ solution, and FeCl 3 solution were mixed in a ratio of 10:1:1 (v/v/v) and pre-reacted at 37 °C for 15 minutes. 0.95 ml of FRAP reagent was added to 0.05 ml of each sample, and the reaction was performed at 37 °C for about 15 minutes, and the absorbance was measured at 590 nm. The results are shown in Fig. 6.
도 6에 나타난 바와 같이, FRAP 환원력은 2 mg/ml의 농도에서 비교예 1은 0.789 OD593 nm인 반면에, 실시예 1 및 실시예 2는 1.566 OD593 nm 및 1.502 OD593 nm의 높은 활성을 보였다. As shown in Fig. 6, the FRAP reducing power of Comparative Example 1 was 0.789 OD 593 nm at a concentration of 2 mg/ml, while Examples 1 and 2 showed high activities of 1.566 OD 593 nm and 1.502 OD 593 nm , respectively.
이들 결과로부터 본 발명에 따른 발효조성물은 항산화 활성이 현저히 증진됨을 알 수 있다.From these results, it can be seen that the fermented composition according to the present invention has significantly enhanced antioxidant activity.
시험예 4: 소화효소 저해활성 검정Test Example 4: Digestive Enzyme Inhibition Activity Test
본 발명에 따른 산양삼새싹의 홍국균 발효조성물에 대해 항당뇨(당뇨 개선) 효과의 지표인 알파-글루코시다아제 저해활성을 검정하였고, 항비만(비만 개선) 지표인 췌장 리파아제 저해활성을 검정하였다.Alpha-glucosidase inhibitory activity, which is an indicator of anti-diabetic (diabetes improvement) effect, was tested for the fermented composition of wild ginseng sprouts and Hongguk fungus according to the present invention, and pancreatic lipase inhibitory activity, which is an indicator of anti-obesity (obesity improvement) effect, was tested.
<알파-글루코시다아제 저해활성><Alpha-glucosidase inhibitory activity>
분석시료 30 ㎕에 알파-글루코시다아제 (0.5 U/ml) 효소용액 70 ㎕, 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37℃에서 10분간 예비반응하였다. 이후 인산나트륨 완충용액(pH 6.8)에 녹인 p-NPG (10 mM) 100 ㎕를 첨가하여 다시 37℃에서 10분 반응시켰으며 반응액에 Na2CO3 (100 mM) 750 ㎕를 첨가해 반응을 정지시킨 후 420 nm에서 분광광도계를 이용하여 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 분석시료 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 7에 나타냈다.30 ㎕ of the analysis sample, 70 ㎕ of an enzyme solution of alpha-glucosidase (0.5 U/ml) and 50 ㎕ of a 200 mM sodium phosphate buffer solution (pH 6.8) were mixed and pre-reacted at 37℃ for 10 minutes. Then, 100 ㎕ of p-NPG (10 mM) dissolved in sodium phosphate buffer solution (pH 6.8) was added and reacted again at 37℃ for 10 minutes. After stopping the reaction by adding 750 ㎕ of Na 2 CO 3 (100 mM) to the reaction solution, the absorbance was measured using a spectrophotometer at 420 nm. For the negative control, an extraction solvent was used instead of the sample, and the difference in absorbance between the group with and without the analysis sample addition was expressed as a percentage (%), and the results are shown in Fig. 7.
도 7에 도시된 바와 같이, 알파-글루코시다아제 저해활성은 2.0 mg/ml 처리 시 비교예 1에서 19.84%로 나타났으나, 실시예 1에서는 45.66% 및 실시예 2에서는 40.58%로 증진되었다.As shown in Figure 7, the alpha-glucosidase inhibitory activity was 19.84% in Comparative Example 1 when treated at 2.0 mg/ml, but was increased to 45.66% in Example 1 and 40.58% in Example 2.
따라서 본 발명에 따른 발효조성물은 알파-글루코시다아제 저해활성이 현저히 증진되어 혈당저하 활성이 우수하여 당뇨 개선효과가 증진됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention has significantly enhanced alpha-glucosidase inhibitory activity, excellent blood sugar lowering activity, and thus enhanced diabetes improvement effect.
<췌장-리파아제 저해활성><Pancreatic lipase inhibitory activity>
분석시료 30 ㎕에 췌장 리파아제 (0.5 U/ml) 효소용액 70 ㎕ 및 200 mM 인산나트륨 완충용액(pH 6.8) 50 ㎕를 혼합하여 37 ℃에서 10분간 예비반응시켰다. 반응 후 인산나트륨 완충용액에 녹인 p-NPB(10 mM) 100 ㎕를 첨가하여 동일하게 10분간 반응시킨 후 100 mM Na2CO3 750 ㎕를 첨가해 반응을 종결시켜 420 nm에서 흡광도를 측정하였다. 음성대조구는 시료 대신에 추출용매를 취하였으며 시료용액의 첨가구와 무첨가구 사이의 흡광도 차이를 백분율(%)로 나타내어 그 결과를 도 8에 나타냈다.30 ㎕ of the analysis sample was mixed with 70 ㎕ of an enzyme solution of pancreatic lipase (0.5 U/ml) and 50 ㎕ of a 200 mM sodium phosphate buffer solution (pH 6.8), and the mixture was pre-reacted at 37 °C for 10 minutes. After the reaction, 100 ㎕ of p-NPB (10 mM) dissolved in sodium phosphate buffer was added, and the mixture was reacted in the same manner for 10 minutes. Then, 750 ㎕ of 100 mM Na 2 CO 3 was added to terminate the reaction, and the absorbance was measured at 420 nm. For the negative control, an extraction solvent was used instead of the sample, and the difference in absorbance between the groups with and without the addition of the sample solution was expressed as a percentage (%), and the results are shown in Fig. 8.
도 8에 도시된 바와 같이, 췌장 리파아제 저해활성은 2.0 mg/ml 처리 시 비교예 1에서 15.46%로 나타났으나, 실시예 1에서는 48.46% 및 실시예 2에서는 44.33%로 더 높은 활성을 보였다. As shown in Figure 8, the pancreatic lipase inhibitory activity was 15.46% in Comparative Example 1 when treated with 2.0 mg/ml, but it showed higher activity at 48.46% in Example 1 and 44.33% in Example 2.
따라서 본 발명에 따른 발효조성물은 췌장 리파아제 저해활성이 증진되어 비만 개선효과가 강화됨을 알 수 있다.Therefore, it can be seen that the fermented composition according to the present invention has enhanced pancreatic lipase inhibitory activity and thus an enhanced obesity improvement effect.
상기 활성(기능성) 검정 결과들로부터, 본 발명에 따른 발효조성물은 진세노사이드 Rg2, F1, PPT, Rd, Rd2, F2, Rg3 및 PPD의 함량이 증진될 뿐만 아니라, 우수한 항산화 활성, 항당뇨 및 항비만 활성을 가져서 기능성 식품 및 화장품의 소재로 유용하다는 것을 알 수 있다.From the above activity (functionality) test results, it can be seen that the fermented composition according to the present invention not only increases the contents of ginsenosides Rg2, F1, PPT, Rd, Rd2, F2, Rg3 and PPD, but also has excellent antioxidant activity, anti-diabetic activity and anti-obesity activity, making it useful as a material for functional foods and cosmetics.
Claims (12)
ⅰ) 산양삼새싹 90~94 중량% 및 콩 6~10 중량%를 혼합한 후 물을 5~10배(v/w)으로 혼합하여 5~7시간 수화하는 단계;
ⅱ) 100~120℃에서 30~60분 증자하는 단계; 및
ⅲ) 홍국균을 3~10%(v/w) 농도로 접종하여 25~30℃에서 8~12일간 발효하는 단계를 포함하는 것인 방법.
A method for producing a fermented composition of wild ginseng sprouts enriched with ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, wherein the method
i) A step of mixing 90 to 94 wt% of wild ginseng sprouts and 6 to 10 wt% of soybeans, then mixing with water in a ratio of 5 to 10 times (v/w) and hydrating for 5 to 7 hours;
ⅱ) Steaming step at 100~120℃ for 30~60 minutes; and
ⅲ) A method including a step of inoculating Honggukgyun at a concentration of 3 to 10% (v/w) and fermenting at 25 to 30°C for 8 to 12 days.
In claim 7, the Hong Guk Myeon fermentation composition of mountain ginseng sprouts is prepared by enhancing ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, wherein the Hong Guk Myeon is at least one selected from the group consisting of Monascus pilosus and Monascus purpureus .
A fermented composition of wild ginseng sprouts with Hongsugung fungus, fortified with ginsenosides Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxatriol and protopanaxadiol, manufactured by a manufacturing method according to Article 8.
An antioxidant functional food containing a fermented composition of wild ginseng sprouts with red yeast according to Article 9.
Functional food for improving diabetes and obesity, containing a fermented composition of wild ginseng sprouts according to Article 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210149719A KR102750984B1 (en) | 2021-11-03 | 2021-11-03 | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210149719A KR102750984B1 (en) | 2021-11-03 | 2021-11-03 | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20230064287A KR20230064287A (en) | 2023-05-10 |
KR102750984B1 true KR102750984B1 (en) | 2025-01-06 |
Family
ID=86386466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210149719A Active KR102750984B1 (en) | 2021-11-03 | 2021-11-03 | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102750984B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101980450B1 (en) | 2017-11-15 | 2019-05-20 | 경남과학기술대학교 산학협력단 | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100635132B1 (en) * | 2004-09-10 | 2006-10-17 | 이인경 | Manufacturing method of red ginseng ginseng |
-
2021
- 2021-11-03 KR KR1020210149719A patent/KR102750984B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101980450B1 (en) | 2017-11-15 | 2019-05-20 | 경남과학기술대학교 산학협력단 | Composition of active wild-cultivated ginseng having increased ginsenoside Rd and compound K, chlorgenic acid and quercetin, and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
한국생물공학회지. Vol.23. No.6. pp.463-469 |
한국환경과학회: 학술대회논문집. Vol. 25. pp.247 |
Also Published As
Publication number | Publication date |
---|---|
KR20230064287A (en) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101482873B1 (en) | Fermentation metabolite of Dendropanax morbiferus produced by liquid-state fermentation and manufacturaring process for the same | |
KR101963978B1 (en) | Composition of fermented sprout ginseng having increased ginsenosides Rh2 and compound K, bioactive components, and preparation method thereof | |
KR101769184B1 (en) | Preparation for fermented ginseng or red ginseng extract containing increased ginsenoside Rd | |
KR102364062B1 (en) | Composition for anti-inflammation containing active mountain-cultivated ginseng and preparation method thereof | |
KR101805737B1 (en) | Manufacturing method for fermented Panax ginseng powder and Fermented Panax ginseng powder manufactured by the method | |
KR101274755B1 (en) | Red ginseng with enhanced specific gensenoside content and producing method thereof | |
KR101372400B1 (en) | A manufacturing method of red ginseng staf4h with enhanced trace ginsenoside | |
KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
KR20130093371A (en) | Novel preparation method of mulberry leaf extract for anti-hypertensive, anti-diabetic, and anti-aging and the product of the same | |
KR102055287B1 (en) | Composition using fermented wood-cultivated ginseng and fermented balloon flower and manufacturing method thereof | |
KR101877225B1 (en) | Method for Manufacturing Tablet Containing Fermented Ginseng and Maca | |
KR102750984B1 (en) | A Monascus fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR102819360B1 (en) | A mushroom-mycelium fermented composition of mountain-cultivated ginseng sprout with increased ginsenoside F3, Rg2, F1, Rd, Rd2, F2, Rg3, protopanaxadiol and protopanaxatriol and a preparation method thereof | |
KR20200132439A (en) | Method for Manufacturing Fermented Ginseng Tablet | |
KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
KR102464052B1 (en) | Composition of complex-fermented sprout ginseng having increased ginsenoside F2, Rg3, Rd2 and compound K, chlorogenic acid, coumaric acid, catechin and quercetin, and preparation method thereof | |
KR100857767B1 (en) | Manufacturing method of ginseng extract from ginseng fruit | |
KR20200049356A (en) | Platycodon grandiflorum Liquid composition for stick-type container having increased ginsenosides of human body absorption type, and preparation method thereof | |
KR102545365B1 (en) | Fermentation composition of mountain-cultivated ginseng having increased ginsenoside Rd, Rc and Protopanaxadiol by using Tricholoma matsutake mycelium and preparation method thereof | |
KR102557683B1 (en) | Fermentation composition of sprouts of mountain-cultivated ginseng having increased ginsenoside Rg3 and Protopanaxadiol, Rutin, Chlorogenic acid and Essential amid acids by using Tricholoma matsutake mycelium and preparation method thereof | |
KR101980684B1 (en) | Method For Producing Ginseng Flower Extract With Enhanced Ginsenoside F4 Content and The Cosmetic Composition Including The Sam | |
KR20230031411A (en) | Method of manufacturing black maekmundong and liquid preparations enhanced steroidal saponin contents and antioxidant activity by fermentation and nine steam and dry | |
KR102834629B1 (en) | A composition of sprouts of ginseng fermented by using Tricholoma matsutake mycelium having increased veratric acid, naringenin, ginsenoside Ro and protopanaxadiol | |
KR102789495B1 (en) | A food composition for inner beauty containing a bioconversion product of extranct of siraitia grosvenorii as an active ingredient | |
KR102564529B1 (en) | Fermentation composition of complex-fermented of Fabaton soybean leaves by using Tricholoma matsutake mycelium and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20211103 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240418 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241224 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20250102 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20250102 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |